Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On April 24, 2017, the Board of Directors of Xenetic Biosciences,
Inc. (the Company) appointed James F. Parslow as the Companys
principal accounting officer, effective immediately. Mr. Parslow
will continue to serve in his current roles as the Companys Chief
Financial Officer and principal financial officer in addition to
his newly appointed role of principal accounting officer.
Mr. Parslow, age 52, has served as the Companys Chief Financial
Officer since April 3, 2017. Prior to joining the Company, he
served as Chief Financial Officer, Treasurer and Secretary of
World Energy Solutions, Inc., a publicly-traded
business-to-business e-commerce company brokering energy and
environmental commodities, from 2006 until its acquisition by
EnerNOC, Inc. in 2015. From 2015 until April 2017, he served as
an independent consultant providing interim chief financial
officer services to multiple emerging technology companies. Mr.
Parslow is a Certified Public Accountant with more than 25 years
of experience serving private and public companies in the
alternative energy, online auction, and high-tech manufacturing
industries. He holds an A.B. in Economics and Accounting from the
College of the Holy Cross and an M.B.A. with a concentration in
Finance from Bentley University.
Mr. Parslow was not appointed to serve as principal accounting
officer to any arrangements or understandings with the Company or
with any other person, and there are no related party
transactions between Mr. Parslow and the Company that would
require disclosure under Item 404(a) of Regulation S-K. His
compensation will not be changed in connection with his
designation as principal accounting officer.
| Item 5.08 | Shareholder Director Nominations. |
On April 24, 2017, the Board of Directors scheduled the Companys
2017 annual meeting of stockholders (the Annual Meeting) for July
18, 2017. The Board has also established the close of business on
May 23, 2017 as the record date for determining stockholders
entitled to receive notice of and to vote at the Annual Meeting.
In accordance with the rules and regulations of the Securities
and Exchange Commission (the SEC) and the Companys Amended and
Restated Bylaws, notice by a stockholder of any qualified
stockholder proposal or qualified stockholder nominations must be
received by the Company at its principal executive offices at 99
Hayden Avenue, Suite 230, Lexington, Massachusetts 02421 and
directed to the attention of the Corporate Secretary by May 8,
2017, which is the eleventh (11th) day following the date of this
Current Report on Form 8-K. Such stockholder proposals or
nominations must conform to the rules and regulations promulgated
by the SEC and the Companys Amended and Restated Bylaws. Any such
notice received after the close of business on May 8, 2017 will
be considered untimely and not properly brought before the Annual
Meeting. All stockholder proposals and nominations must comply
with applicable Nevada law, the rules and regulations promulgated
by the SEC, and the procedures set forth in the Companys Amended
and Restated Bylaws.
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII. Xenetic Biosciences, Inc. (NASDAQ:XBIO) Recent Trading Information
Xenetic Biosciences, Inc. (NASDAQ:XBIO) closed its last trading session up +0.08 at 4.57 with 16,222 shares trading hands.
